$MAIA has achieved patient enrollment milestones in its Phase 2 and pivotal Phase 3 NSCLC trials. Part C of THIO-101 is fully enrolled, while THIO-104 has reached 65% of its 2026 enrollment target. Read more: bit.ly/4y6RAde

$MAIA has received regulatory approval in Spain and Portugal to begin screening patients in its pivotal Phase 3 THIO-104 trial evaluating ateganosine in NSCLC. To date, THIO-104 has enrolled 60 NSCLC patients across existing sites. Read: bit.ly/4cVo6aE

$MAIA has reached 65 randomized patients in its pivotal Phase 3 THIO-104 trial evaluating ateganosine as a third-line treatment for advanced NSCLC. The trial currently has 38 activated sites across six countries. Read more: bit.ly/4yQ0o83

$MAIA has dosed the first U.S. patient in its Phase 2 THIO-101 expansion trial, evaluating ateganosine in third-line NSCLC. The U.S. expansion is supported by a $2.3M NIH grant and the study has now enrolled patients across four continents. Read more: bit.ly/4reXYx2

MAIA Biotechnology Announces Open Market Purchases of Company Stock by Long-Standing Board Member and CEO. Read more: bit.ly/4h6Y4Ce $MAIA

$MAIA presented two studies at #IRT2026 covering novel divalent cancer RedOx-activatable prodrugs and dual-pharmacophore dinucleotide prodrugs. Preclinical testing identified molecular features associated with increased antitumor activity. Read more: bit.ly/4hlg2lO

We’re proud to share that MAIA Biotechnology has been nominated for the 2026 Prix Galien USA Award in the Best Startup category. Thank you to @GalienFdn for this recognition. We look forward to the awards ceremony this October. prn.to/4zvZ9fA $MAIA

Thank you @Benzinga for highlighting MAIA’s latest Phase 2 THIO-101 clinical update - including a 90.5% disease control rate in third-line NSCLC patients receiving ateganosine followed by cemiplimab. bit.ly/4vC3UB3 $MAIA

From telomere biology to clinical development, MAIA Chairman & CEO Dr. Vlad Vitoc explains how ateganosine, a first-in-class investigational telomere-targeting agent, is being developed as a treatment for third-line NSCLC. Watch: bit.ly/4pKHfkR $MAIA @SullyOnTheAir

Initial efficacy observations from Part C of the Phase 2 THIO-101 trial remained consistent with previously reported THIO-101 clinical activity, despite evaluating a more heavily pre-treated third-line NSCLC patient population. Learn more: bit.ly/4h3mBtz $MAIA

MAIA Biotechnology reported positive initial efficacy data from Part C of its Phase 2 THIO-101 trial, including a 90.5% disease control rate in third-line NSCLC patients receiving ateganosine followed by cemiplimab. Learn more: bit.ly/4h3mBtz $MAIA

From enrollment momentum to clinical site expansion, June brought several notable milestones for MAIA Biotechnology's clinical programs evaluating ateganosine in advanced NSCLC. Discover @Channelchek's recap here: bit.ly/4fbkSB6 $MAIA

MAIA Biotechnology completed international enrollment in Part C of its Phase 2 THIO-101 expansion trial evaluating ateganosine in advanced NSCLC patients receiving third-line therapy. Patient screening continues at three U.S. clinical sites. Learn more: bit.ly/4etBeF5

The THIO-101 expansion trial continues to evaluate ateganosine as a third-line treatment in patients with advanced NSCLC who have previously received checkpoint inhibitors and chemotherapy. Read the latest update: bit.ly/3PVZA0O $MAIA

MAIA has opened enrollment at @winshipatemory, the third U.S. clinical site participating in the Phase 2 THIO-101 expansion trial evaluating ateganosine as a third-line treatment for advanced NSCLC. Learn more: bit.ly/44gbh5J $MAIA

As MAIA advances its pivotal Phase 3 THIO-104 trial, the study continues to evaluate ateganosine as a potential third-line treatment option for patients with advanced NSCLC who have progressed following prior therapies. Learn more about the trial: bit.ly/43ekpYo $MAIA

Momentum continues in the expansion of the THIO-101 trial. MAIA Biotechnology has activated its second U.S. clinical site for the ongoing Phase 2 expansion trial evaluating ateganosine as the 3L treatment in advanced #NSCLC. Read more: bit.ly/3PVZA0O $MAIA

MAIA Biotechnology provided a patient enrollment update for its pivotal Phase 3 THIO-104 trial evaluating ateganosine in advanced #NSCLC. The company is targeting up to 100 patients by year-end and expects an interim analysis in 2027. Read more: bit.ly/43ekpYo $MAIA

MAIA CEO Vlad Vitoc and Director Stan Smith increased their ownership positions through open market purchases of MAIA common stock. The continued investments underscore confidence in MAIA's telomere-targeting immuno-oncology platform. Learn more: bit.ly/4eitt4v $MAIA

Over the weekend at #ASCO26, MAIA CEO Vlad Vitoc and Dr. Tomasz Jankowski presented the company's THIO-104 Trial in Progress poster. The level of engagement surrounding MAIA's clinical programs remains encouraging. Learn more about THIO-104: bit.ly/4amOSam $MAIA